Senior Managing Director & Representative Director, Ono Pharmaceutical Co., Ltd.
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Ono Pharmaceutical Co., Ltd. 4528 · FY ending Mar 2026 · Senior Managing Director & Representative Director |
Own name | 59,000 | — | ¥2,512 | ¥148M | ¥4.7M |
| Year | Net worth | Pay | Dividends | Total income | Taxes (est.) | After tax (est.) | Share sales (after tax) |
|---|---|---|---|---|---|---|---|
| 2026 | ¥148M | ¥129M | ¥4.7M | ¥134M | ¥66.0M | ¥65.7M | — |
| 2025 | ¥61.3M | ¥111M | ¥3.0M | ¥114M | ¥55.6M | ¥56.4M | — |
| 2024 | ¥68.7M | ¥84.4M | ¥2.2M | ¥86.6M | ¥40.6M | ¥44.1M | — |
Grouped by the calendar year of each company's fiscal year-end. Years in which the person was not among the top 10 shareholders of a company exclude that company.